A BST RACT : Background: Increased extracellular glutamate may contribute to L-dopa induced dyskinesia, a debilitating side effect faced by Parkinson's disease patients 5 to 10 years after L-dopa treatment. Therapeutic strategies targeting postsynaptic glutamate receptors to mitigate dyskinesia may have limited success because of significant side effects. Increasing glutamate uptake may be another approach to attenuate excess glutamatergic neurotransmission to mitigate dyskinesia severity or prolong the time prior to onset. Initiation of a ceftriaxone regimen at the time of nigrostriatal lesion can attenuate tyrosine hydroxylase loss in conjunction with increased glutamate uptake and glutamate transporter GLT-1 expression in a rat 6-hydroxydopamine model. In this article, we examined if a ceftriaxone regimen initiated 1 week after nigrostriatal lesion, but prior to L-dopa, could reduce L-dopa-induced dyskinesia in an established dyskinesia model. Methods: Ceftriaxone (200 mg/kg, intraperitoneal, once daily, 7 consecutive days) was initiated 7 days post-6-hydroxydopamine lesion (days 7-13) and continued every other week (days 21-27, 35-39) until the end of the study (day 39 postlesion, 20 days of L-dopa). Results: Ceftriaxone significantly reduced abnormal involuntary movements at 5 time points examined during chronic L-dopa treatment. Partial recovery of motor impairment from nigrostriatal lesion by L-dopa was unaffected by ceftriaxone. The ceftriaxone-treated L-dopa group had significantly increased striatal GLT-1 expression and glutamate uptake. Striatal tyrosine hydroxylase loss in this group was not significantly different when compared with the L-dopa alone group. Conclusions: Initiation of ceftriaxone after nigrostriatal lesion, but prior to and during L-dopa, may reduce dyskinesia severity without affecting L-dopa efficacy or the reduction of striatal tyrosine hydroxylase loss. Parkinson's disease (PD) is characterized by loss of nigrostriatal dopamine (DA) neurons and tyrosine hydroxylase (TH) 1-3 with nigrostriatal terminal fields being more vulnerable early in the disease process.
Parkinson's disease (PD) is characterized by loss of nigrostriatal dopamine (DA) neurons and tyrosine hydroxylase (TH) [1] [2] [3] with nigrostriatal terminal fields being more vulnerable early in the disease process. 3 With the progressive degeneration of DA neurons, evidence for concomitant increases in glutamatergic tone have been observed, [4] [5] [6] [7] [8] [9] [10] [11] including decreased striatal glutamate uptake and changes in glutamate transporter GLT-1 function. [11] [12] [13] High concentrations of synaptic glutamate increase Ca 21 influx through the glutamate receptors triggering activation of Ca 21- dependent enzymes that can lead to excitotoxic cell death. [14] [15] [16] [17] [18] [19] [20] Increased Ca 21- dependent phosphorylation of TH occurs with TH loss in the rat 6-hydroxydopamine (6-OHDA) PD model 21 and is reduced in conjunction with increased glutamate uptake.
lead to L-dopa-induced dyskinesia (LID), affecting 50% of patients by the first 5 years of L-dopa therapy and 90% of patients after 10 years of therapy. [23] [24] [25] These dyskinesias limit the therapeutic efficacy of Ldopa and disrupt the quality of life in PD patients. Furthermore, once dyskinesia appears, it re-emerges with subsequent exposure to L-DOPA, therefore remaining a significant challenge to mitigate motor impairment.
The development of LID has been attributed to plasticity in pre-and postsynaptic receptor and transporter functions in striatum, [26] [27] [28] [29] [30] [31] [32] including glutamatergic imbalances, [33] [34] [35] [36] [37] [38] [39] [40] that may arise from DA neuron loss or L-dopa treatment. 40 The only current U.S. Food and Drug Administration approved drug for mitigating LID expression is amantadine, 25, [41] [42] [43] a N-methyl-D-aspartate antagonist that, among others, may have limited clinical utility in some cases 44 and produced untoward side effects such as psychiatric and memory complications. 35, 45, 46 Recent work has focused on the pharmacological blockade of glutamate receptors directed at alternate subtypes. However, it is not resolved as to whether an antidyskinetic effect, similar or superior to that of amantadine, may be achieved by other glutamate receptor drugs, such as metabotropic glutamate receptor modulators. 35, 47, 48 The pharmacological-based reduction of striatal or nigral glutamate efflux may reduce LID severity. [49] [50] [51] GLT-1 is a primary glial glutamate transporter responsible for clearing synaptic glutamate 52 and may be involved in neurodegenerative processes. 11, [15] [16] [17] [18] Ceftriaxone, a beta-lactam antibiotic, can increase GLT-1 expression with >5 consecutive daily injections. 11, [53] [54] [55] When initiated at the time of 6-OHDA, thereby increasing GLT-1 expression during the progression of TH loss, ceftriaxone can attenuate TH loss 9 days after 6-OHDA lesions in association with the increased uptake of glutamate and reduced Ca 21 -dependent phosphorylation of TH.
11 Increased GLT-1 expression by ceftriaxone may also reduce DA neuron loss when initiated prior to 56 or after 11, 57, 58 the experimental DA lesion. We reasoned that ceftriaxone may reduce LID by augmenting glutamate uptake or reducing the rate of TH loss using an established model of LID. 59, 60 The timing of ceftriaxone administration was modeled in accordance with consideration of the time required to ensure increased GLT-1 expression 11, [53] [54] [55] and the longevity of its effect of at least 1 week 11 and was initiated at a time postlesion when TH loss has been shown to be >50%. 11, 21, 30, 61 The appearance of PD locomotor symptoms are generally considered to be present with >70% loss of striatal TH, but recent evidence suggests that symptoms can present with as little as a 35% loss in putamen. 3 The possible clinical translation therefore was to initiate ceftriaxone when significant striatal TH protein loss was expected and end the first 7-day regimen prior to L-dopa initiation. As such, our paradigm sought to model a preventive strategy to reduce LID severity or time of onset when locomotor symptoms would begin and a PD patient would begin taking L-dopa. The weeklong ceftriaxone regimen continued intermittently thereafter, with a subsequent week-on, week-off regimen, until L-dopa was given for 20 days, 39 days post-6-OHDA lesion.
Methods Animals
Male Sprague Dawley rats (N 5 38 used across all replicate studies) purchased from Charles River (Worchester, MA, USA) were used in all experiments. All rats were 4 to 9 months old in the study and were housed under controlled lighting conditions (12:12 reverse light:dark cycle) with food and water available ad libitum. All animals were used in compliance with Office of Laboratory Animal Welfare guidelines and an approved protocol by the institutional Animal Care and Use Committee at Louisiana State University Health Sciences Center-Shreveport, University of North Texas Health Science Center, and Binghamton University. The study was conducted in replicate at the 3 institutions, with the University of North Texas Health Science Center additionally evaluating amphetamine-induced rotational motor function and Binghamton assessing forepaw adjustment steps in response to L-dopa with and without ceftriaxone.
Ceftriaxone and L-Dopa Treatment
The overall study design is illustrated in Figure 1 . On day 7 post-6-OHDA lesion, ceftriaxone (200 mg/kg, intraperitoneal [i.p.]) or saline was administered for 7 consecutive days and every other week (days 7-13, 21-27, and [35] [36] [37] [38] [39] . Ceftriaxone (disodium salt hemiheptahydrate; Hospira, Lake Forest, Illinois, or Toronto Research Chemicals, Inc., Toronto, Ontario, no. C245000) was dissolved in sterile saline (0.9%) and prepared daily. The dose of L-dopa (Sigma, no. D9628) at 1 experiment site was 12 mg/kg L-dopa and 6 mg/kg L-dopa (methyl ester; Cayman Chemical, 16149, Ann Arbor, MI, USA) was used at the 2 subsequent studies. In combination with 15 mg/kg benserazidehydrochloride, i.p., L-dopa was given for 20 consecutive days, starting on day 19 (day 1 of L-dopa) until day 39 postlesion. No significant difference in total axial, limb, orolingual (ALO) was observed between using either dose of L-dopa in either the L-dopa alone (experiment site, F 1,5 5 1.55, P 5 .27; days of L-dopa, F 5,25 5 26.0, P < .0001) or L-dopa 1 ceftriaxone group (experiment site, F 1,11 5 1.09, P 5 .32; days of L-dopa, F 5,55 52.44, P < .05), and therefore study outcomes were collapsed between study sites.
6-OHDA Lesions
Rats were anesthetized with 40 mg/kg pentobarbital i.p. (Lundbeck Inc., Deerfield, Illinois) with supplements of 9.0, 0.6, and 0.3 mg/kg ketamine, xylazine, and acepromazine, respectively, or with 2% to 3% continuous inhalation isoflurance. The rats were immobilized in a stereotaxic frame to target the medial forebrain bundle (coordinates ML 11.5, AP 23.8, DV 28.0) relative to Bregma according to the Paxinos and Watson rat brain atlas. 62 6-OHDA (16 lg in 4 ll [4 lg/ll, Tocris (Minneapolis, MN, USA) as hydrobromide no. 2547 or Sigma-Aldrich (St Louis, MO, USA), as hydrobromide no. 162957]) in 0.02% ascorbic acid (4 mg/ml) was infused unilaterally at 1 ll/min into the medial forebrain bundle. The contralateral medial forebrain bundle was infused with vehicle (0.02% ascorbic acid).. The needle (26 gauge) was left in place for 10 minutes before removal. Body temperature was maintained at 378C using a heating pad.
Behavioral AIMS Ratings
L-dopa-induced abnormal involuntary movements (AIMs) were rated by 2 lab members blind to treatment group at 6 time points (days 19, 23, 27, 31, 35, 39 following the 6-OHDA lesion, corresponding to days 1, 4, 7, 12, 17, and 20 of daily L-dopa administration). At 20 minutes after L-dopa, dyskinetic behaviors were quantified based on frequency during a 1-minute observation period performed every 20 minutes during a period of 140 minutes. The following 3 subtypes of AIMs were evaluated: axial AIMs (dystonic posturing of the upper trunk toward the side contralateral to the lesion), limb AIMs (hyperkinetic or jerky movements of the forelimb contralateral to the lesion), and orolingual AIMs (abnormal jaw movements, facial twitching, and tongue protrusion). Each subtype was scored based on a frequency from 0 to 4, with 4 occurring continuously during the entire 1-minute observation period and not being interrupted by an experimentor-generated startling sound. 59, 60 Total AIMs scores were calculated by summing the total score from each 20-minute observation period. Theoretically, the highest AIMs score achievable in 1 test day would be 84. This scoring system has been used in a previous study from our lab 30 and others.
59,60,63

Forepaw Adjusting Steps (FAS)
The FAS test measures rat forelimb akinesia, modeling clinical symptoms of PD. Rats with greater than 80% striatal DA depletion perform poorly on the task and L-dopa treatment partially reverses lesion-induced deficits. 64, 65 For this test, 1 experimenter held both hind legs and 1 forepaw such that the rat was bearing its weight on the forepaw to be tested. Rats are moved across the table at a speed of 90 cm/10 seconds, during which an additional experimenter recorded the number of adjusting steps taken on the weight-bearing forepaw. Both experimenters were blinded to treatment condition. Rats were dragged for 6 trials per forepaw: 3 backhand (lateral steps away from the torso) and 3 forehand (lateral steps toward the torso) trials, alternating the starting forepaw between animals. Data were represented as the sum of the 3 trials per direction for each forepaw (ie, left forehand). Fewer steps indicate greater lesion-induced akinesia. This test was used in 1 of 3 replicate studies performed to verify nigrostriatal lesion evidence and to evaluate if ceftriaxone affected L-dopa-dependent motor recovery. There was no significant difference in FAS at baseline measure taken at day 7 postlesion, just prior to the ceftriaxone initiation in designated groups. There were also baseline assessments of forepaw adjusting steps (FAS) on day 7 postlesion, followed by assessments on days 1, 7, and 17 of L-dopa treatment. L-dopa alone group, n 5 11; L-dopa 1 ceftriaxone group, n 5 18; ceftriaxone alone group, n 5 9, across 3 study sites. All groups received unilateral 6-hydroxydopamine (6-OHDA) lesions.
Amphetamine-Induced Rotation
Amphetamines produce rotations in unilaterally lesioned rats, with a high probability of lesion between 50 to 100 rotations per hour. 66 We used this test in a replicate study to verify that rats entering 2 treatment groups (L-dopa or L-dopa 1 ceftriaxone) had at least 50 rotations present on day 7 postlesion. Amphetamine (2 mg/kg, i.p.) was given on day 7 following 6-OHDA and rotations were quantified for 1 hour following injection. There was no significant difference in amphetamine-induced rotation between the L-dopa alone and L-dopa 1 ceftriaxone groups (P 5 .31, df 5 9) . Rats in the L-dopa 1 ceftriaxone group had 137 6 27 rotations (mean 6 SEM, n 5 8).
Preparation of Synaptosomes and Glutamate Uptake
To evaluate the relationship of GLT-1 expression with glutamate uptake with and without ceftriaxone, striatal glutamate uptake was determined on the last day of LID assessment in 1 of the replicate studies. Synaptosomes were prepared as previously described. 11 Striatal tissue was homogenized at 48C in 5 mL of 0.32 M sucrose solution then spun at 1000g for 10 minutes. The resulting P1 fraction was stored frozen until processing for TH protein determination. The supernatant was spun further at 16,500g for 30 minutes at 48C, yielding the P2 fraction, and aspirated and resuspended in 1 mL of Kreb's buffer. The P2 fraction was used to determine GLT-1 expression and glutamate uptake. Protein concentration was determined using the bichinchoninic acid assay (Thermo Scientific, Rockford, Illinois).
Glutamate Uptake Protocol
The synaptosomal P2 fraction contains glial components, 67 and approximately 70% of the levels of glial fibrillary acid protein are recovered in purified glial plasmalemmal vesicles and used to assess glutamate uptake. 11, 22 Uptake was assessed in a 200-lL final volume by reconstituting 30 lg synaptosomal protein in 100 lL in oxygenated Kreb's buffer at 48C. Synaptosomes were heated to 358C for 5 minutes, followed by 100 lL of 10 lM 14C(U)-L-glutamic acid (PerkinElmer, Waltham, Massachusetts; specific activity 260 mCi/mmol, no. NEC290E050UC) to give the 5-lM final glutamate. Uptake time was 90 seconds and terminated with 1 ml of ice-cold Kreb's buffer. The reuptake time was as close as practically possible to glutamate reuptake time in vivo. 68, 69 Synaptosomes were washed to remove excess labeled glutamate with equal-osmolarity phosphate-buffered saline buffer through a Brandel M24-TI cell harvester (Brandel, Gaithersburg, MD, USA). The percent of labeled glutamate recovered was calculated for uptake as pmole/ mg protein/min.
Tissue Preparation and Western Immunoblotting
Synaptosome fractions (P1, P2) were sonicated in 1% sodium dodecyl sulfate solution (pH 8). Following electrophoresis, the proteins were transferred onto nitrocellulose (Bio-Rad Laboratories), stained with Ponceau S, and normalized for protein via relative staining. These lanes were scanned and quantified by Image J (imagej. nih.gov/ij/) for further normalization to total protein. The membranes were then blocked in polyvinylpyrrolidone buffer (1% polyvinylpyrrolidone and 0.05% Tween 20) and exposed to the primary antibody for 2 hours. Specific primary antibodies were GLT-1 (Santa Cruz, Santa Cruz, California, no. 15317) and TH (Millipore (Temecula, CA, USA)), no. AB152). The P2 fraction was used to assess GLT-1 expression, and the P1 fraction was used for TH expression, comparing the TH protein expression per protein in lesioned versus the contralateral side against a standard curve of TH protein standard. 11, 21, 30, 61 The TH protein was also determined from processing fresh frozen striatal dissections obtained at the conclusion of 2 replicate studies, as previously described. 11 No significant difference in TH loss was observed by the lesion in the L-dopa 1 ceftriaxone group as a result of the preparation method of tissue for analysis (t 5 1.57, nonsignificant, df 5 11). Nominal protein loads for linear detection of GLT-1 was 25-lg total protein and 5 to 8 lg for striatal TH. Secondary antibodies (swine antirabbit IgG) were used for signal enhancement, followed by 1-hour incubation with (125I) protein A (PerkinElmer) or a chemilluminscence approach using a secondary antibody (Immun-Star no.170-5046, goat anti-rabbit) from BioRad (Hercules, CA, USA) and quantified using BioRad imager V3 ChemiDoc Touch.
Statistics
Data were analyzed using Graphed Prism (GraphPad, La Jolla, California) or Statistica (Tulsa, OK, USA) with correction for multiple comparisons and pvalues < 0.05 considered significant. A 2-way analysis of variance (time 3 treatment) was used to analyze the sum of the ALO AIM scores obtained for each day of the dyskinesia evaluation followed by Bonferroni multiple-comparison post hoc tests to determine if significant differences in total ALO were present for each day of evaluation between the L-dopa alone versus the L-dopa 1 ceftriaxone groups. There were few (maximum ALO observed 5 3) or no AIMs observed in the ceftriaxone alone (no L-dopa) group in 2 replicate studies (median value of 1; total n 5 9). This group was used to verify that ceftriaxone itself would not produce AIMS comparable to those in the L-dopa alone group. Therefore, the statistical evaluations were kept between the L-dopa alone and L-dopa 1 ceftriaxone groups.
FAS data were analyzed with a 3-way analysis of variance (paw 3 treatment 3 time) to determine whether
forepaw stepping in the intact or lesioned paw differed depending on treatment and/or session (days 1, 7, or 17 of L-dopa treatment). When main effects or interactions were found, a Bonferroni multiple comparison-Dunn post hoc test was employed to determine if significant differences existed between conditions.
Correlational analyses (Pearson) evaluated GLT-1 expression versus glutamate uptake. A paired-student test determined if the differences in glutamate uptake were observed between lesioned and unlesioned striatum for each of the 3 treatment groups. No significant differences between lesioned and unlesioned sides were observed in any group. Thus, the average uptakes between lesioned and unlesioned sides were used to determine differences in uptake existed between the 2 AIMS-relevant groups (unpaired t test), as little or no AIMS in the CEF alone treatment group was observed. An unpaired t test was used to evaluate TH protein loss between the L-dopa 1 ceftriaxone and L-dopa alone groups.
Results
Chronic Ceftriaxone Reduces L-Dopa-Induced Dyskinesia Expression
In the 6-OHDA 1 ceftriaxone, no L-dopa group, 7 of 9 total rats exhibited a total ALO of 1 or 0. Therefore, any LID produced by ceftriaxone alone in . Two-way repeated measures analyses of variance (matched for individual test subject over time) revealed a significant effect of duration of L-dopa administration (F 5,90 513.84, P < .0001) and treatment (F 1,18 517.40, P 5 .0006). There was also significant interaction between the duration of L-dopa and ceftriaxone treatment (F 5,90 5 3.83, P 5 .0034). Significant differences between the 2 groups were observed on 5 of the 6 observation days (day 1, t 5 2.57, nonsignificant; day 4, t 5 3.35, **P < .01; day 7, t 5 4.30, ***P < .001; day 12, t 5 4.33, ***P < .001; day 17, t 5 4.37,***P < . 16.94, P 5 .0006. Significant differences were observed 20-to 120-minutes after L-dopa. Statistical outcomes: *P < .05, **P < .01, ***P < .001, ****P < .0001. Results not depicted in graphs. Day 4: time interval after L-dopa, F 6,108 5 9.09, P < .0001; effect of ceftriaxone treatment, F 1,18 5 9.46, P 5 .0.007. Significant differences were observed 60-to 140-minutes after L-dopa. Day 12: time interval after L-dopa, F 6,108 5 12.08, P < .0001; effect of ceftriaxone treatment, F 1,18 5 18.77, P 5 .0004. Significant differences were observed at 20-to 120-minutes after L-dopa. Day 20: time interval after L-dopa, F 6,108 5 8.31, P < .0001; effect of ceftriaxone treatment, F 1,18 5 14.21, P 5 0.001. Significant differences were observed at 20-to 120-minutes after L-dopa.
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lesioned rats was negligible, and statistical comparisons of LID thereafter were between the L-dopa alone versus the L-dopa 1 ceftriaxone group. With the described ceftriaxone regimen (Fig. 1) , LID severity, shown as total ALO AIMS, was decreased in all but the first 6 days of observation throughout the study when compared with L-dopa alone ( Fig. 2A) . The mean reduction of total ALO in the L-dopa 1 ceftriaxone group across all days of observation was 75 6 4% (mean 6 standard deviation). The reduction of total AIMS in the ceftriaxone group was evident earlier after L-dopa injection as the regimen of L-dopa continued, such that AIMS reduction was significant at the first 20-minute observation   FIG. 3 . Forepaw adjusting steps. Effects of 6-OHDA lesion, L-dopa treatment, and L-dopa 1 ceftriaxone (Cef) on forepaw adjusting steps (FAS). At 7 days after 6-OHDA lesion surgery, rats (4-5/group) were assessed to establish baseline FAS differences between lesioned (A) and unlesioned (B) forelimbs. Following baseline FAS, the animals received daily Cef (CF; 0 or 200 mg/kg, i.p.) in a 7 day on, 7 day off treatment paradigm over 32 days. L-dopa (0 or 6 mg/kg, i.p.) treatment began 19 days after lesion and continued daily for 19 days. Adjusting steps were recorded 60-minutes post-L-dopa treatment and are presented as group mean lesioned forepaw stepping 1 standard error of the mean (SEM). Parametric 3 3 2 3 4 (treatment 3 paw 3 day) analyses of variance were used to assess differences. Main effects of paw (F 1,22 5 138.5, P < .001) and time (F 3,66 5 3.6, P < .02) were found. Importantly, a 3-way interaction between factors was also revealed (F 1,22 5 3.6, P < .004). Bonferroni post-hoc tests demonstrated significant improvements in stepping with L-dopa regardless of Cef treatment on days 1 and 7 versus baseline (*P < .05 vs baseline of the same treatment condition).
FIG. 4.
GLT-1 expression and glutamate uptake. (A) Striatal GLT-1 protein expression is directly correlated with glutamate uptake. Combining all treatment groups, a significant positive correlation was observed between striatal GLT-1 protein expression and glutamate uptake (Pearson r 5 0.762, P < .0001). Note, symbols on the graph (᭺, ceftriaxone alone; *, L-dopa 1 ceftriaxone; x, L-dopa alone) represent the values obtained from each of the three treatment groups (taken from both lesioned [L] and unlesioned striatum [UL]). (B) GLT-1 expression in lesioned striatum. The ceftriaxone regimen produced a significant increase in GLT-1 expression, without any difference in relative expression levels observed between the unlesioned striatum (data not shown) and the lesioned striatum. In the lesioned striatum, GLT-1 expression was significantly increased in the 2 groups receiving ceftriaxone (L-dopa 1 ceftriaxone group vs L-dopa alone, data shown). Student unpaired t test, t 5 4.81, P < .01, df 5 7. (C) Glutamate uptake. Striatal glutamate uptake (average uptake values from unlesioned and lesioned striatum of each test subject used for analysis) was greater in the Cef 1 L-dopa versus L-dopa alone treated rats. Student unpaired t test, t 5 2.56, *P < .05, df 5 6.
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period by day 7 of L-dopa and continued until 120 minutes or later after L-dopa was given (Fig. 2B-D) .
Antiparkinson Effects of L-Dopa Were Not Affected by Ceftriaxone
The FAS test evaluates nigrostriatal lesion severity by comparing the adjustment steps of the forepaw contralateral to the side of lesion versus the forepaw contralateral to the unlesioned side. As depicted in Figure 3 , the number of steps taken with the lesioned forepaw (Fig. 3A) were significantly reduced by 6-OHDA lesion to near 70% less than that of the unlesioned side (Fig. 3B) . L-dopa treatment increased the number of lesioned paw steps taken versus those at baseline both 1 and 7 days 7 postlesion (Fig. 3A) , and this improvement in motor performance was similar in the L-dopa 1 ceftriaxone group (Fig. 3A) .
GLT-1 Protein Expression and Glutamate Uptake
Confirming the proposed role of brain GLT-1, there was a significant positive correlation found between striatal GLT-1 expression and glutamate uptake (Fig.  4A) . Importantly, when comparing striatal GLT-1 expression in the unlesioned striatum across treatments, the L-dopa 1 ceftriaxone group had significantly increased expression compared to the L-dopa alone group (t 5 5.03, p < .01, df 5 7, unpaired t test). This pattern of effects was also seen in the 6-OHDA lesioned striatum (Fig. 4B) . No differences in uptake were observed between unlesioned and lesioned striata (data not shown), so the combined average uptake was used to compare uptake between L-dopa 1 ceftriaxone and L-dopa alone groups, given that only these 2 groups presented ALO AIMS. The Ldopa 1 ceftriaxone group showed significant increases in glutamate uptake compared to the L-dopa alone group (Fig. 4C) .
Ceftriaxone Treatment and Striatal Tyrosine Hydroxylase Expression
There was no significant difference in striatal TH protein loss between the L-dopa alone versus the Ldopa 1 ceftriaxone group (Fig. 5) . Striatal TH loss in the L-dopa 1 ceftriaxone group had a 4-fold greater coefficient of variance than the L-dopa alone group, suggesting the possibility that the severity of TH loss may have correlated with total ALO among test subjects. However, striatal TH loss in the L-dopa 1 ceftriaxone group (Pearson r 5 0.344, P 5 .25, 13 pairs) or the L-dopa alone group (Pearson r 5 0.348, P 5 .44, 8 pairs) did not correlate with the total ALO observed among the test subjects.
Discussion
Given L-dopa's primary role and significant efficacy in the treatment of motor symptoms, but noted side effects, unveiling neurobiological strategies to mitigate LID still remain a critical clinical hurdle. 70 The aim of this study was to determine if ceftriaxone, previously shown in preclinical studies to increase GLT-1 expression, 11, [53] [54] [55] could reduce LID severity or time of onset. The cellular source of increased GLT-1 expression by ceftriaxone is likely astocytes, 57 although a neuronal GLT-1 component may not be ruled out. 71 Ceftriaxone also can activate other potentially protective signaling pathways, 58, 72 which were not evaluated in our study. The regimen of ceftriaxone used herein decreased dyskinesia rating scores by approximately 70%. We also observed increased GLT-1 expression and glutamate uptake, indicating that the increase in GLT-1 expression could reduce extracellular glutamate levels by way of concomitant increases in glutamate uptake. The regimen of ceftriaxone regimen began when TH protein loss would be expected to be at least 50% (as evidenced by confirmation of amphetamine-induced rotations at the start of the ceftriaxone regimen and possibly approximately 70%-80%, as shown in previous studies 11, 21, 30, 61 ). The possible translation of this study would be that if PD symptoms were detected and L-dopa was being considered for pharmacotherapy, increasing the GLT-1 expression could alleviate the severity or delay the onset of dyskinesia. To add to the translational potential of this study, the ceftriaxone regimen did not appear to alter the beneficial effects of L-dopa and thus may convey a favorable clinical profile. A logical extension of this work would include interventional ceftriaxone after L-dopa has begun. In this regard, the FIG. 5. Tyrosine hydroxylase protein loss. Striatal TH loss by 6-OHDA at the end of the study was measured by comparison of the percent of tyrosine hydroxylase (TH) protein in the lesioned versus contralateral control striatum in each test subject. There was no significant difference in TH loss between the L-dopa and Cef 1 L-dopa groups (t 5 1.85, P 5 .08, nonsignificant, df 5 18). The variance in TH protein loss was significantly different (coefficient of variance 5 17% in L-dopa alone vs 65% in Cef 1 L-dopa) between the 2 groups (F 12,6 5 7.04, P < .05).
results serve as proof of principle that ceftriaxone could also be effective in established LID because the current ceftriaxone regimen was intermittent. GLT-1 loss has been observed in 6-OHDA lesion PD and MPTP models. 7, 11, 12, 73 We have previously reported decreased glutamate uptake in association with approximately 80% loss of TH in the 6-OHDA model. 11 Therefore, increased GLT-1 and glutamate uptake may reduce LID severity by reducing excess glutamatergic neurotransmission, as seen with observations showing reduced LID in association with reduced glutamate release. 49, 50 To the converse, others have not reported any difference in striatal glutamate concentrations in the lesioned nigrostriatal pathway, 10, 74, 75 which may be attributed to timedependent changes in release and uptake and their contributions to extracellular glutamate concentration and when these determinations were made after lesion induction or the lesion site. 4, 5, 40, 75 As a result, postlesion time points and lesion topography are relevant metrics for timing therapeutic strategies. The postsynaptic involvement of glutamate-mediated mechanisms in the long-term effects of L-dopa therapy has been well documented. Pathologically enhanced corticostriatal plasticity may influence LID presentation with glutamate receptors implicated in this process. Increased sensitivity of striatal glutamate AMPA receptors [36] [37] [38] in dyskinetic rats and AMPA receptor blockade may attenuate the process of priming for LID in animal models of PD. As such, future inquiries to evaluate if modulation of glutamate uptake or release would alter AMPA receptor function or expression in conjunction with differences in LID onset or severity could be informative.
Presynaptic alterations with chronic L-dopa, however, have been less examined. The few studies with chronic L-dopa report increased GLT-1 expression, 13, 76, 77 which could be a compensatory response to alleviate excessive synaptic glutamate accumulation or maintain stores of glutamate for cystine/glutamate antiporter, 33 an exchanger responsible for glutathione synthesis. Our data would suggest that such an intrinsic increase in GLT-1 may not be sufficient to delay LID expression, but may constitute a logical target for pharmacological augmentation. Accordingly, the ability of ceftriaxone and L-dopa to increase GLT-1 expression more than L-dopa alone suggests that this increase could reach the threshold of the level of GLT-1 expression necessary to prevent or reduce LID.
The expression of other glutamate transporters was not determined in these studies, although we previously reported that ceftriaxone does not affect GLAST expression. 11 Another consideration with regard to using the contralateral striatum as our control is the issue of clinical translation, given our use of the unilateral 6-OHDA model and known bilateral projections in the basal ganglia. 78 However, the hemiparkisonian PD model used here was intended for comparison of TH loss against contralateral striatum. As such, our results showed a nonsignificant trend toward reduced TH loss in the L-dopa 1 ceftriaxone group when compared with the L-dopa alone group. This lack of effect by ceftriaxone on striatal TH loss, when beginning 7 days after lesion induction, contrasts with our previous observation that ceftriaxone protects against striatal TH protein loss if initiated at the time of 6-OHDA lesion induction. 11 This difference in striatal TH loss being dependent on the timing of ceftriaxone initiation indicates that excess extracellular glutamate may contribute to striatal TH loss. However, others have reported a possible restorative effect on nigrostriatal function by ceftriaxone. Ceftriaxone alone (no L-dopa) reduced AIMs in 6-OHDA lesioned rats long after its cessation and for a time period nearly double (69 days) that in our study. 79 It is possible that DA function altered by ceftriaxone outside of the striatum could be associated with such locomotor effects. 80 In conclusion, the ability of ceftriaxone-induced increased GLT-1 expression to persist under long-term L-dopa treatment and alleviate LID in a rodent PD model presents evidence that increased glutamate uptake could be a viable therapeutic target for reducing LID development or severity. Moreover, the reduction of dyskinesia was not apparently associated with the loss of antiparkinsonian effects of L-dopa. This work represents a stepping stone for further evaluation of ceftriaxone as a viable, inexpensive and available and antidyskinetic compound, as it has been proven to be safe as a repurposed drug in other neurodegenerative diseases. 81 
